{"nctId":"NCT05136885","briefTitle":"HEALEY ALS Platform Trial - Regimen E SLS-005 - Trehalose","startDateStruct":{"date":"2022-02-21","type":"ACTUAL"},"conditions":["Amyotrophic Lateral Sclerosis"],"count":161,"armGroups":[{"label":"SLS-005","type":"EXPERIMENTAL","interventionNames":["Drug: SLS-005"]},{"label":"Matching Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Matching Placebo"]}],"interventions":[{"name":"SLS-005","otherNames":[]},{"name":"Matching Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* No additional inclusion criteria beyond the inclusion criteria specified in the Master Protocol (NCT NCT04297683).\n\nExclusion Criteria:\n\n* The following exclusion criteria are in addition to the exclusion criteria specified in the Master Protocol (NCT NCT04297683).\n\n  1. Current diagnosis or healthcare professional-recommended treatment (medication, exercise or diet) of diabetes mellitus\n  2. Master Protocol screening glucose \\>140 mg/dl\n  3. Prior treatment with IV trehalose or known hypersensitivity to trehalose\n  4. Current use of oral trehalose (see prohibited medication Section 5.9)\n  5. Inability for participant to return to site for weekly drug administration, until approved for home infusions","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Disease Progression as Assessed by the ALSFRS-R Slope","description":"Change in disease severity over time as measured by the ALS Functional Rating Scale-Revised (ALSFRS-R). Each type of function is scored from 4 (normal) to 0 (no ability), with a maximum total score of 48 and a minimum total score of 0. Patients with higher scores have more physical function.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.91","spread":"0.090"},{"groupId":"OG001","value":"-1.06","spread":"0.091"}]}]}]},{"type":"PRIMARY","title":"Mortality Event Rate","description":"Mortality is defined as death or death equivalent. A participant is determined to meet the criteria of death equivalent if permanent assisted ventilation (PAV) is used for more than 22 hours per day for more than seven days in a row. The rate of mortality was estimated from a Bayesian shared-parametric model that assumed exponentially distributed survival times.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.010","spread":"0.0025"},{"groupId":"OG001","value":"0.012","spread":"0.0027"}]}]}]},{"type":"SECONDARY","title":"Respiratory Function","description":"Change in respiratory function over time as measured by Slow Vital Capacity (SVC).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-11.40","spread":"1.431"},{"groupId":"OG001","value":"-10.85","spread":"1.089"}]}]}]},{"type":"SECONDARY","title":"Muscle Strength","description":"Change in muscle strength over time as measured isometrically using hand-held dynamometry (HHD).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-26.19","spread":"2.568"},{"groupId":"OG001","value":"-27.11","spread":"1.876"}]}]}]},{"type":"SECONDARY","title":"Number of Participants That Experienced Death or Death Equivalent","description":"The number of participants who died or met the criterion for a death equivalent from the date of their baseline visit to the end of the Week 24 visit window (generally 175 days after baseline). The death equivalent criterion is the use of permanent assisted ventilation (PAV) for more than 22 hours per day for more than 7 days in a row.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"10","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":19,"n":120},"commonTop":["Fall","Muscular weakness","Fatigue","Neuromyopathy","Constipation"]}}}